DJIA 17,131.97 100.83 0.59%
NASDAQ 4,552.76 33.86 0.75%
S&P 500 1,998.98 14.85 0.75%
market minute promo

3.92 0.01 (0.26%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

ARNA $3.92 0.26%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $3.92
Previous Close $3.91
Daily Range $3.85 - $4.05
52-Week Range $3.82 - $7.97
Market Cap $861.8M
P/E Ratio -15.04
Dividend (Yield) $0.00 (0.0%)
Volume 4,559,281
Average Daily Volume 4,064,970
Current FY EPS -$0.35





Arena Pharmaceuticals, Inc. (ARNA) Description

A clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. Website:

News & Commentary Rss Feed

2 New Diet Drugs Coming Soon?

Orexigen Therapeutics and Novo Nordisk are close to bringing new diet drugs to market. But will doctors prescribe them?

Orexigen Therapeutics Wins Contrave Approval But Investors Should Stay Away

Doc Offers Glimpse Into Arena Pharma Weight-Loss Combination Therapy

Orexigen Falls After Approval - Why?

Arena And Vivus Ruined The FDA Approval Run Up For Orexigen

Novo Gets Positive Vote From FDA For Anti-Obesity Treatment - Still A Long Road Ahead

Belviq Sales See Holiday Dip - Still On Track

Surprising New Competitor: Should Arena Pharmaceuticals, Inc. and Orexigen Therapeutics, Inc. Be Afr

A new weight loss pill from Orexigen will face stiff competition from Arena's Belviq and may soon have to compete against Novo Nordisk's Saxenda.

FDA Approves Orexigen Therapeutics Inc.'s Goldilocks Obesity Drug

Orexigen and Takeda's Contrave has the right balance of efficacy and safety.

Orexigen's Obesity Pill is Approved and Stock Falls. Don't be Surprised

See More ARNA News...

ARNA's Top Competitors

ARNA $3.92 (0.26%)
Current stock: ARNA
AMGN $139.33 (0.99%)
Current stock: AMGN
GILD $104.76 (3.73%)
Current stock: GILD
BIIB $326.88 (2.11%)
Current stock: BIIB